Page 4 - Inflarx Commitment Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Inflarx commitment program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Inflarx Commitment Program Today - Breaking & Trending Today

InflaRx (NASDAQ:IFRX) Short Interest Up 933.4% in April

InflaRx (NASDAQ:IFRX – Get Rating) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 1,890,000 shares, an increase of 933.4% from the March 31st total of 182,900 shares. Based on an average trading volume of 2,300,000 shares, the days-to-cover ratio […] ....

Nicolas Fulpius , Niels Christoph Riedemann , Renfeng Guo , Raymond James , Raymond James Financial Services Advisors Inc , Millennium Management , Invesco Ltd , Renaissance Technologies , Get Rating , Montreal Can , James Financial Services Advisors , Inflarx Daily , Nasdaq Ifrx ,

HC Wainwright Trims InflaRx (NASDAQ:IFRX) Target Price to $9.00

InflaRx (NASDAQ:IFRX – Get Rating) had its target price trimmed by HC Wainwright from $10.00 to $9.00 in a report released on Friday, The Fly reports. The firm currently has a buy rating on the stock. Other equities analysts have also issued research reports about the company. Lifesci Capital raised InflaRx from a market perform […] ....

Renfeng Guo , Nicolas Fulpius , Niels Christoph Riedemann , Raymond James , Millennium Management , Invesco Ltd , Raymond James Financial Services Advisors Inc , Renaissance Technologies , Get Rating , Montreal Can , James Financial Services Advisors , Inflarx Daily , Nasdaq Ifrx , Lower Price Target , Hc Wainwright ,

InflaRx N.V.: InflaRx Announces Closing of $40 Million Public Offering of Ordinary Shares

JENA, Germany, April 14, 2023 (GLOBE NEWSWIRE) InflaRx N.V. (Nasdaq: IFRX) (the "Company"), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement ....

Sankt Peterburg , United States , Regina Lutz , Inflarx Gmb , Katja Arnold , Laurie Doyle , Drug Administration , Lifesci Capital , Raymond James Associates Inc , European Medicines Agency , Mc Services , Inflarx Pharmaceuticals Inc , Exchange Commission , Equity Syndicate , Raymond James , Inflarx Pharmaceuticals , Ann Arbor ,

InflaRx Announces Closing of $40 Million Public Offering of Ordinary Shares

JENA, Germany, April 14, 2023 InflaRx N.V. , a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today that it has. | April 14, 2023 ....

United States , Sankt Peterburg , Regina Lutz , Katja Arnold , Inflarx Gmb , Laurie Doyle , Raymond James Associates Inc , European Medicines Agency , Lifesci Capital , Inflarx Pharmaceuticals Inc , Globenewswire Inc , Exchange Commission , Equity Syndicate , Mc Services , Drug Administration , Sci Capital , Medicines Agency , Inflarxnv Stock Exchange , Press Release , T Ifrx Nl0012661870 ,

InflaRx N.V.: InflaRx Announces Public Offering of Ordinary Shares

JENA, Germany, April 11, 2023 (GLOBE NEWSWIRE) InflaRx N.V. (Nasdaq: IFRX) (the "Company"), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement ....

United States , Sankt Peterburg , Katja Arnold , Laurie Doyle , Regina Lutz , Inflarx Gmb , Raymond James Associates Inc , European Medicines Agency , Mc Services , Equity Syndicate , Exchange Commission , Lifesci Capital , Inflarx Pharmaceuticals Inc , Drug Administration , Raymond James , Inflarx Pharmaceuticals , Ann Arbor ,